Group 1: Company Overview and Strategic Moves - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. has over 1,000 pharmaceutical clients across more than 40 countries, providing a market entry and customer connection channel for its subsidiary, Kema Biotechnology [2] - The company is entering the AI innovative drug research and development field, responding to the global trend where major pharmaceutical companies are integrating AI into their strategic core [2] - The investment in Kema Biotechnology is seen as the first step in the company's strategic layout in AI innovative drug R&D, aiming to enhance technical service capabilities and foster new growth curves [2] Group 2: Product Development and Regulatory Status - The transition of the pen-type injector aluminum cap to "A" status allows the company to provide an integrated supply capability for core components of pen-type injectors, enhancing its competitive edge [3] - This transition also establishes a self-controlled supply chain for high-end pharmaceutical packaging materials, which have historically been dominated by international companies [3] - The company aims to meet the growing demand for high-end pen-type injector packaging materials, positively impacting future operational performance [3] Group 3: Collaboration and Market Expansion - The collaboration with Ganli Pharmaceutical Co., Ltd. is progressing well, with the recent regulatory approval strengthening this partnership [3] - The company is actively expanding its customer base, with positive developments reported in this area [3] Group 4: Shareholder Confidence and Future Outlook - The controlling shareholder's intention to increase shareholding reflects confidence in the company's long-term investment value and stable future development [4] - The company will disclose its full-year performance for 2025 in its annual report, which will be available on the designated information platform [4]
华兰股份(301093) - 2025年11月18日投资者关系活动记录表